SAB Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . SAB Biotherapeutics
SABSW Stock  USD 0.07  0  4.43%   
SAB Biotherapeutics financial statements provide useful quarterly and yearly information to potential SAB Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on SAB Biotherapeutics financial statements helps investors assess SAB Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting SAB Biotherapeutics' valuation are summarized below:
Revenue
1.5 M
Earnings Share
0.292
Quarterly Revenue Growth
2.077
Revenue Per Share
0.175
There are over one hundred nineteen available fundamental measures for SAB Biotherapeutics, which can be analyzed over time and compared to other ratios. All traders should should double-check SAB Biotherapeutics' latest fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to drop to about 36.1 M in 2024. Enterprise Value is likely to climb to about (12 M) in 2024

SAB Biotherapeutics Total Revenue

2.13 Million

Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 3.9 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 16.12, Dividend Yield of 0.0 or PTB Ratio of 0.7. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of SAB Biotherapeutics Correlation against competitors.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

SAB Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets63.5 M83.9 M34.3 M
Slightly volatile
Short and Long Term Debt Total5.5 M5.9 M7.2 M
Slightly volatile
Other Current Liabilities8 M5.9 M3.3 M
Slightly volatile
Total Current Liabilities14.6 M10.8 M8.2 M
Slightly volatile
Property Plant And Equipment Net25.2 M24.7 M14.6 M
Slightly volatile
Accounts Payable898.6 K945.9 K2.6 M
Pretty Stable
Cash59.4 M56.6 M16 M
Slightly volatile
Non Current Assets Total25.4 M25 M14.6 M
Slightly volatile
Long Term Debt654 K622.9 K204.4 K
Slightly volatile
Cash And Short Term Investments59.4 M56.6 M16 M
Slightly volatile
Common Stock Shares Outstanding9.4 M5.5 M30.6 M
Slightly volatile
Liabilities And Stockholders Equity63.5 M83.9 M34.3 M
Slightly volatile
Non Current Liabilities Total9.4 M15.8 M14 M
Slightly volatile
Capital Lease Obligations4.8 M4.9 M6 M
Slightly volatile
Other Current Assets2.7 M2.3 M1.1 M
Slightly volatile
Other Stockholder Equity82.4 M147.3 M48.4 M
Slightly volatile
Total Liabilities27.5 M26.6 M22.4 M
Slightly volatile
Property Plant And Equipment Gross30.2 M34.6 M17.2 M
Slightly volatile
Short and Long Term Debt604.8 K1.1 M1.1 M
Slightly volatile
Total Current Assets38.1 M58.9 M19.7 M
Slightly volatile
Capital Stock8879344.4 K
Slightly volatile
Net Working Capital50.5 M48.1 M13.3 M
Slightly volatile
Short Term Debt2.1 M2.7 M1.9 M
Pretty Stable
Common Stock8839293.3 K
Slightly volatile
Current Deferred Revenue1.4 M1.3 M267.4 K
Slightly volatile
Other Assets32.6 M36.7 M40 M
Slightly volatile
Non Currrent Assets Other327.2 K350.2 K450.5 K
Slightly volatile
Accumulated Other Comprehensive Income21.1 K23.8 K25.9 K
Slightly volatile

SAB Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income80.1 K130.8 K97.5 K
Slightly volatile
Depreciation And Amortization3.9 M3.7 M1.1 M
Slightly volatile
Interest Expense289.4 K315.3 K397 K
Slightly volatile
Selling General Administrative15 M23.8 M8 M
Slightly volatile
Total Revenue2.1 M2.2 M11.9 M
Slightly volatile
Other Operating Expenses28.5 M40.3 M17.8 M
Slightly volatile
Research Development32.1 M16.5 M16.7 M
Slightly volatile
Total Operating Expenses28.5 M40.3 M17.8 M
Slightly volatile
Reconciled Depreciation3.9 M3.7 M981.6 K
Slightly volatile
Cost Of Revenue3.2 M3.7 M2 M
Slightly volatile
Selling And Marketing Expenses3 M3.4 M3.7 M
Slightly volatile

SAB Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2 M2.4 M961.3 K
Slightly volatile
Begin Period Cash Flow13 M15 M12.3 M
Very volatile
Other Cashflows From Financing Activities70.5 M67.2 M15 M
Slightly volatile
Depreciation3.9 M3.7 M984.5 K
Slightly volatile
Capital Expenditures187.3 K197.2 K2.7 M
Slightly volatile
Total Cash From Financing Activities70.1 M66.8 M16.7 M
Slightly volatile
End Period Cash Flow34 M56.6 M16.4 M
Slightly volatile
Change To Inventory387.9 K436.4 K475.1 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio16.1216.9665858
Slightly volatile
Days Sales Outstanding15697.57234
Slightly volatile
Average Payables4.1 M2.3 M4.5 M
Slightly volatile
Stock Based Compensation To Revenue1.141.08250.2317
Slightly volatile
Capex To Depreciation0.050.05263.6925
Pretty Stable
Payables Turnover4.163.95940.8976
Slightly volatile
Sales General And Administrative To Revenue11.1610.62952.3185
Slightly volatile
Research And Ddevelopement To Revenue7.747.37612.7591
Slightly volatile
Capex To Revenue0.08370.08810.1872
Very volatile
Cash Per Share10.7610.24472.8689
Slightly volatile
Days Payables Outstanding87.5892.1862826
Slightly volatile
Current Ratio5.725.44762.5221
Slightly volatile
Receivables Turnover3.163.872.2551
Slightly volatile
Graham Number26.6242.24113.1709
Slightly volatile
Capex Per Share0.03390.03570.7827
Slightly volatile
Average Receivables2.6 M2.8 M12.2 M
Slightly volatile
Revenue Per Share0.390.40553.4067
Slightly volatile
Interest Debt Per Share0.350.39270.203
Slightly volatile
Debt To Assets0.0210.02210.0818
Slightly volatile
Operating Cycle53.1576.3652.7147
Slightly volatile
Days Of Payables Outstanding87.5892.1862826
Slightly volatile
Ebt Per Ebit1.111.10821.0323
Very volatile
Quick Ratio5.725.44762.5221
Slightly volatile
Net Income Per E B T1.121.151.0524
Slightly volatile
Cash Ratio5.495.23111.8634
Slightly volatile
Days Of Sales Outstanding15697.57234
Slightly volatile
Fixed Asset Turnover0.08620.09070.6292
Pretty Stable
Debt Ratio0.0210.02210.0818
Slightly volatile
Price Sales Ratio16.1216.9665858
Slightly volatile
Asset Turnover0.02530.02670.2785
Pretty Stable

SAB Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap36.1 M38 M3 B
Slightly volatile

SAB Fundamental Market Drivers

Cash And Short Term Investments56.6 M

About SAB Biotherapeutics Financial Statements

SAB Biotherapeutics investors use historical fundamental indicators, such as SAB Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SAB Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.3 M1.4 M
Total Revenue2.2 M2.1 M
Cost Of Revenue3.7 M3.2 M
Stock Based Compensation To Revenue 1.08  1.14 
Sales General And Administrative To Revenue 10.63  11.16 
Research And Ddevelopement To Revenue 7.38  7.74 
Capex To Revenue 0.09  0.08 
Revenue Per Share 0.41  0.39 
Ebit Per Revenue(17.01)(16.16)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GOOGAlphabet Inc Class C
CRMSalesforce

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY